Inhibition of NLRP3 inflammasome activation has been shown to alleviate steatohepatitis (Jang et al., 2023), making the NLRP3 inflammasome a potential therapeutic target for NAFLD. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.